

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study*

Kimberly K. Leslie, Michael W. Sill, Edgar Fischer, Kathleen M. Darcy, Robert S. Mannel, Krishnansu S. Tewari, Parviz Hanjan, Jason A. Wilken, Andre T. Baron, Andrew K. Godwin, Russell J. Schilder, Meenakshi Singh, Nita J. Maihle

Keywords: Gefitinib; endometrial cancer; epidermal growth factor receptor (EGFR); soluble EGFR; estrogen receptor; progesterone receptor

Background

A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer.

Methods

Women with histologically confirmed persistent/recurrent endometrial cancer were treated with 500 mg oral gefitinib daily until progression or severe toxicity, with progression-free survival (PFS) at six months as the primary endpoint. Tumor expression of total epidermal growth factor receptor (EGFR), estrogen receptor (ER), progesterone receptor A (PRA) and B (PRB), Ki67, pEGFR and activated extracellular signal-regulated kinase (pERK) were examined pre- and post-treatment. EGFR was sequenced, and serum concentrations of soluble EGFR (sEGFR) at baseline also were examined.

Results

Of 29 patients enrolled, 26 were

evaluable for efficacy and toxicity. Four patients experienced PFS \geq 6 months, and one had a complete response which was not associated with an EGFR mutation. The concentration of sEGFR in pretreatment serum was positively correlated with overall survival (OS), but not with responsiveness to gefitinib in this small patient cohort. Expression of tumor biomarkers was not associated with PFS or OS. Co-expression of ER with PRA in primary and recurrent tumors, and pEGFR with pERK in primary tumors was observed.

Conclusions

This treatment regimen was tolerable but lacked sufficient efficacy to warrant further evaluation in this setting. The possible association between serum sEGFR concentrations and OS, and temporal changes in expression of pEGFR and pERK and the documented CR of one patient are interesting and warrant additional investigation.

This study was supported by the National Cancer Institute grants to the Gynecologic Oncology Group

**Leslie KK, Sill MW, Fischer E, Darcy KM, Mannel RS, Tewari KS, Hanjani P, Wilken JA, Baron AT, Godwin AK, Schilder RJ, Singh M, Maihle NJ. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Jun;129(3):486-94. doi: 10.1016/j.ygyno.2013.02.019. Epub 2013 Feb 21. PubMed PMID: 23438670*

This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

(GOG) Administrative Office, the GOG Core Laboratory for Receptors and Targets and the GOG Tissue Bank (CA 27469), the GOG Statistical and Data Center (CA 37517), K. Leslie (R01-CA099908), A.K. Godwin (R01-CA140323), N. Maihle (R01-CA79808), as well as support from Susan G Komen for the Cure and the Marsha Rivkin Foundation for Ovarian Cancer Research (to J. Wilken). We also thank and acknowledge the Barbara Beach Fund to support endometrial cancer research (to K. Leslie).